Cordyceps Militaris and the EU Novel Food Line

Executive Summary

In August 2025, the European Commission clarified the status of Samsoniella hepiali, the fungus behind most commercial "Cordyceps CS-4" extract. In food supplements, it is not novel^[3]NutraIngredients (2025). Cordyceps 'boom' on the horizon as novel food status of S. hepiali clarified. NutraIngredients Link.

That clarification does not cover Cordyceps militaris. Both the mycelium and the fruiting body remain classified as novel under Regulation (EU) 2015/2283, and both require pre-market authorisation before they can go into an EU food supplement. The Dutch food safety authority stated the same point in its 2025 inspection results: C. militaris is an unauthorised novel food in the EU and may not be sold without prior safety authorisation^[2]Functional Mushrooms EU (2026). EU Novel Food Catalogue: Mushroom Status by Species. functionalmushrooms.eu Link^[8]Netherlands Food and Consumer Product Safety Authority (2025). Inspectieresultaten Cordyceps militaris 2025. NVWA Link.

The trade name "cordyceps" is therefore not specific enough for an EU-bound formula. Species identity decides the regulatory route.

1. Species, Not Trade Names

Species	Traded as	EU food-supplement status	Basis
Ophiocordyceps sinensis (wild)	"Cordyceps sinensis," "wild cordyceps"	Not novel	Documented EU consumption before 15 May 1997
Samsoniella hepiali (fermented mycelium)	"Cordyceps CS-4"	Not novel in food supplements (confirmed August 2025)	European Commission clarification, August 2025[3]NutraIngredients (2025). Cordyceps 'boom' on the horizon as novel food status of S. hepiali clarified. NutraIngredients Link
Cordyceps militaris (fruiting body or mycelium, cultivated)	"Cordyceps militaris," "Cordyceps Militaris Extract"	Novel - requires authorisation before EU food-supplement sale	No documented significant EU consumption pre-1997; both forms explicitly listed[2]Functional Mushrooms EU (2026). EU Novel Food Catalogue: Mushroom Status by Species. functionalmushrooms.eu Link[8]Netherlands Food and Consumer Product Safety Authority (2025). Inspectieresultaten Cordyceps militaris 2025. NVWA Link

The CS-4 story is mostly a species-identification problem. The fermentation strain sold for decades as "CS-4" was long assumed to be a cultured form of O. sinensis itself. A 2020 multigene phylogenetic study - five genetic markers, run against the holotype material - resolved what the authors describe as a systematic position that had "been puzzling in both business and academic communities for a long time," and formally placed the organism (previously Paecilomyces hepiali) in a new genus, Samsoniella, as a species distinct from O. sinensis^[4]Wang et al. (2020). Multigene phylogeny of the family Cordycipitaceae (Hypocreales): new taxa and the new systematic position of the Chinese cordycipitoid fungus Paecilomyces hepiali. Fungal Diversity 103:1-46 Link. That taxonomic clarity is what let EU regulators rule on the material five years later. The regulation tracks species, not the marketing category.

2. The Pre-1997 Test

Regulation (EU) 2015/2283 defines "novel" by a single test: was the food consumed to a significant degree within the EU before 15 May 1997? If yes, it is exempt. If no, it needs a full EFSA safety dossier before it can be placed on the EU market^[1]European Parliament & Council of the European Union (2015). Regulation (EU) 2015/2283 of the European Parliament and of the Council of 25 November 2015 on novel foods. EUR-Lex Link.

The Novel Food Catalogue treats wild O. sinensis as not novel, and the Commission's August 2025 clarification put S. hepiali in the same position for food supplements^[3]NutraIngredients (2025). Cordyceps 'boom' on the horizon as novel food status of S. hepiali clarified. NutraIngredients Link. The sources reviewed for this article do not set out the consumption evidence behind the S. hepiali decision. C. militaris has no such determination. The catalogue lists it as novel in both mycelium and fruiting-body form, with no carve-out by intended use^[2]Functional Mushrooms EU (2026). EU Novel Food Catalogue: Mushroom Status by Species. functionalmushrooms.eu Link.

This is not a finding that C. militaris failed a safety assessment. It means no authorisation has been granted, and none can be assumed without one.

3. Cordycepin Is Mostly a C. Militaris Story

The compound most associated with cordyceps' claimed bioactivity is cordycepin (3′-deoxyadenosine). In the literature reviewed here, C. militaris is the best-documented source.

A 2022 analytical survey measured cordycepin across cultivated C. militaris material: 25.9 mg/100g dry weight in self-cultivated fruiting bodies, 57.5 mg/100g in commercial fruiting bodies, 60.4 and 81.4 mg/100g in two commercial food supplements, and 6.34 mg/100g in mycelium-only culture - with the authors noting that other published work reports fruiting-body ranges as high as 110-837 mg/100g dry weight, reflecting how strongly cultivar and processing affect the final number^[5]Jędrejko et al. (2022). Cordyceps militaris - Fruiting Bodies, Mycelium, and Supplements: Valuable Component of Daily Diet. Antioxidants 11(10):1861 Link. The same paper cites about 175 mg/100g dry weight for mycelial cultures grown under other conditions, so the low mycelium figure above reflects one culture, not a fixed property of mycelium. We are not aware of a directly comparable cordycepin dataset for wild O. sinensis in the sources reviewed for this article - the traditional-medicine reputation of wild cordyceps rests more on adenosine and polysaccharide content than on cordycepin specifically, and buyers should ask any supplier making a comparative cordycepin claim for the analytical method and sample basis behind it.

For formulators, the awkward part is that the EU-restricted species is also the one most consistently associated with cordycepin yield. The EU decision therefore has to be made before the claim strategy is written.

4. Human Evidence

Before building any performance claim on C. militaris, start with the trial base. A 2026 narrative review identified five human intervention studies (n=321, ages 16-35, published 2017-2024), with daily doses of 1-12g over 1-16 weeks, some of them using multi-ingredient products^[6]Muszyńska et al. (2026). Current Evidence of Ergogenic and Post-Exercise Recovery Effects of Dietary Supplementation with Cordyceps militaris in Humans - A Narrative Review. Nutrients 18(5):781 Link.

Some trials reported improvements in VO₂max/VO₂peak, time to exhaustion, and running performance, along with lower creatine kinase and blood urea nitrogen (markers of muscle damage) and better oxygen saturation during high-intensity effort. The review's own conclusion is more careful than any of those individual results: findings were "inconsistent," and certainty is limited by small sample sizes, heterogeneous protocols, under-reported randomisation, no trial registration in most studies, the use of multi-ingredient supplements, and - notably for anyone specifying material - "absence of standardized preparations with quantified bioactive constituents"^[6]Muszyńska et al. (2026). Current Evidence of Ergogenic and Post-Exercise Recovery Effects of Dietary Supplementation with Cordyceps militaris in Humans - A Narrative Review. Nutrients 18(5):781 Link. The authors call for trials using chemically characterised material before treating efficacy as established.

Section 3 shows cordycepin content varying by more than an order of magnitude across materials. With that spread, a performance claim is only as strong as the specification behind the material actually being shipped.

5. Sourcing Checks

Ask for the binomial, not the trade name. "Cordyceps" on a spec sheet or COA is not sufficient for an EU-bound SKU. Ask for the genus and species, and treat a supplier who can't provide it as a compliance risk before you evaluate anything else about the material.

Don't take morphological identification as final. The CS-4/S. hepiali history is a direct demonstration that visual or culture-based identification misclassified a commercially significant organism for years. Molecular verification is the more defensible standard going forward, particularly for material entering the EU^[4]Wang et al. (2020). Multigene phylogeny of the family Cordycipitaceae (Hypocreales): new taxa and the new systematic position of the Chinese cordycipitoid fungus Paecilomyces hepiali. Fungal Diversity 103:1-46 Link.

Separate your EU strategy from your non-EU strategy. The EU novel food classification applies to the EU market. Other markets use different frameworks; the US, for example, regulates dietary ingredients through New Dietary Ingredient notification and GRAS status rather than a novel food authorisation. Check the rules for each target market rather than assuming one specification serves every market.

Plan for the EU pathway if you need it there. An EFSA novel food authorisation requires a full safety dossier and assessment, and takes years rather than months. If cordycepin content is central to an EU-facing product's claims, that is the real timeline to plan against - not an assumption that authorisation is imminent.

Where This Leaves Our Own Cordyceps

Our cultivated Cordyceps militaris fruiting-body extract falls in the "novel" category above under current EU rules. For EU-bound enquiries, this status needs to be discussed before an order is placed. If a formulation needs both cordycepin content and an EU-market pathway, the regulatory route has to be discussed before the product spec is locked.

---